Robert Francomano - Feb 2, 2023 Form 4 Insider Report for SELLAS Life Sciences Group, Inc. (SLS)

Role
Chief Commercial Officer
Signature
/s/ Robert Francomano
Stock symbol
SLS
Transactions as of
Feb 2, 2023
Transactions value $
$0
Form type
4
Date filed
2/3/2023, 04:14 PM
Previous filing
Mar 15, 2022
Next filing
Dec 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLS Common Stock Award $0 +12K $0.00 12K Feb 2, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLS Stock Option (Right to Buy) Award $0 +45K $0.00 45K Feb 2, 2023 Common Stock 45K $3.34 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person received an award of 12,000 restricted stock units on February 2, 2023, which shall vest as follows: (i) 25% on December 1, 2023 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.
F2 One-quarter (1/4) of the option shares will vest and became exercisable one year from the February 2, 2023 grant date, and the remainder will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.